Patents by Inventor Jean-Luc Girardet

Jean-Luc Girardet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
    Patent number: 8648116
    Abstract: This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also concerns methods of making the compounds and compositions described herein.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: February 11, 2014
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Michel Vernier, Colin Edward Rowlings, Jean-Luc Girardet, Stuart Dimock, Barry Quart, Jeffrey N. Miner
  • Compounds, compositions and methods of using same for modulating uric acid levels
    Patent number: 8633232
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: January 21, 2014
    Assignee: Ardea Biosciences, Inc.
    Inventors: Esmir Gunic, Jean-Luc Girardet, Jean-Michel Vernier, Martina E. Tedder, David A. Paisner
  • NOVEL COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20140005136
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: July 30, 2013
    Publication date: January 2, 2014
    Applicant: Ardea Biosciences, Inc.
    Inventors: Barry D. QUART, Jean-Luc GIRARDET, Esmir GUNIC, Li-Tain YEH
  • POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF
    Publication number: 20130345271
    Abstract: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.
    Type: Application
    Filed: July 30, 2013
    Publication date: December 26, 2013
    Applicant: Ardea Biosciences, Inc.
    Inventors: Irina ZAMANSKY, Gabriel GALVIN, Jean-Luc GIRARDET
  • POLYMORPHIC FORMS OF 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND USES THEREOF
    Publication number: 20130331403
    Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Ardea Biosciences, Inc.
    Inventors: Laszlo R. TREIBER, Irina ZAMANSKY, Jean-Luc GIRARDET
  • N[S(4-aryl-triazol-3-yl)?-mercaptoacetyl]--amino benzoic acids as HIV reverse transcriptase inhibitors
    Patent number: 8552043
    Abstract: A series of S-triazolyl ?-mercaptoacetanilides having N-(?-mercaptoacetyl) p amino benzoic acid derivatives. are provided, where Q is CO2H, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: October 8, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Zhi Hong, Stanley Lang
  • Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
    Patent number: 8546436
    Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: October 1, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Laszlo R. Treiber, Gabriel Galvin, Irina Zamansky, Jean-Luc Girardet
  • Compounds and compositions and methods of use
    Patent number: 8546437
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 1, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh
  • Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4-1,2,4-triazol-3-ylthio) acetate, and uses thereof
    Patent number: 8524754
    Abstract: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: September 3, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Irina Zamansky, Jean-Luc Girardet, Gabriel Galvin
  • TREATMENT OF GOUT AND HYPERURICEMIA
    Publication number: 20130178484
    Abstract: Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
    Type: Application
    Filed: June 14, 2011
    Publication date: July 11, 2013
    Applicant: Ardea Biosciences, Inc.
    Inventors: Jeffrey Miner, Jean-Luc Girardet, Barry D. Quart
  • S-triazolyl ?-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
    Patent number: 8481581
    Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: July 9, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Esmir Gunic, Zhi Hong, Stanley Lang, Hong-Woo Kim
  • TREATMENT OF GOUT
    Publication number: 20130059868
    Abstract: Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses such compositions for the treatment of a variety of diseases and conditions.
    Type: Application
    Filed: March 29, 2011
    Publication date: March 7, 2013
    Applicant: Ardea Biociences, Inc.
    Inventors: Jeffrey Miner, Jean-Luc Girardet, Barry D. Quart
  • Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels
    Publication number: 20130040907
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: May 4, 2012
    Publication date: February 14, 2013
    Applicant: Ardea Biosciences Inc.
    Inventors: Esmir GUNIC, Jean-Luc GIRARDET, Jean-Michel VERNIER, Martina E. TEDDER, David A. PAISNER
  • Compounds, Compositions and Methods of Using Same for Modulating Uric Acid Levels
    Publication number: 20130040963
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: June 4, 2012
    Publication date: February 14, 2013
    Applicant: Ardea Biosciences, Inc.
    Inventors: Esmir GUNIC, Jean-Luc GIRARDET, David A. PAISNER
  • Methods of modulating uric acid levels
    Patent number: 8372807
    Abstract: Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, a compound disclosed herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: February 12, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Martha De La Rosa, Jean-Luc Girardet, Karen Watson
  • Compounds and compositions and methods of use
    Patent number: 8357713
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: January 22, 2013
    Assignee: Ardea Biosciences Inc.
    Inventors: Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh
  • Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
    Patent number: 8354532
    Abstract: This application concerns certain 2-phenylamino-6-aryl amino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines and -deazapurines. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: January 15, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Yung-hyo Koh, Stephanie Shaw, Hong Woo Kim, Zhi Hong
  • Compounds, compositions and methods of using same for modulating uric acid levels
    Patent number: 8344012
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: January 1, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Esmir Gunic, Jean-Luc Girardet, David A. Paisner
  • Substituted thieno [2,3-d] pyrimidines as HIV inhibitors
    Patent number: 8324223
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: December 4, 2012
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Zhi Hong, Stephanie Shaw, Yung-hyo Koh
  • S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
    Publication number: 20120283301
    Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 8, 2012
    Applicant: Ardea Biosciences Inc.
    Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Esmir Gunic, Zhi Hong, Stanley Lang, Woo-Hong Kim